How much did Medpace spend on share repurchases in Q2 2026?

Medpace repurchased 705,616 shares for a total of $294.7 million during the second quarter of 2026, implying an average price of approximately $417.87 per share.

How much authorization remains for future repurchases?

As of June 30, 2026, the company had $527.0 million remaining under its authorized share repurchase program. This gives management substantial capacity to continue buybacks in subsequent periods.

Does this buyback activity reduce future earnings per share?

The company's 2026 full-year EPS guidance ($17.25–$17.95) is explicitly stated not to include the potential impact of any share repurchases after June 30, 2026. Fewer shares outstanding would generally increase per-share earnings, all else equal, but management has not incorporated post-H1 repurchases into its forward guidance.

What was the execution mechanism for these repurchases?

The filing does not specify the mechanism used (e.g., Rule 10b-18 open-market purchases, ASR, or 10b5-1 plan). Such details are often disclosed in later periodic filings rather than in quarterly earnings releases.

Did Medpace have sufficient cash to fund this buyback?

Yes. Medpace held $502.7 million in cash and cash equivalents at June 30, 2026, and generated $162.0 million in operating cash flow during Q2 2026 alone, easily covering the $294.7 million repurchase.

Why doesn't the company's 2026 guidance include the impact of future repurchases?

Management typically excludes potential future buybacks from guidance because the timing, price, and magnitude of repurchases are discretionary and uncertain. The guidance assumes 28.6 million diluted weighted-average shares outstanding for the full year 2026, implying no material buyback impact from July onward.

MEDP 8-K Filed 2026-07-22 Execution disclosure

Medpace repurchased 705,616 shares for $294.7M in Q2 2026

CRO spent $294.7M on buybacks during second quarter with $527.0M remaining under authorization.

Shares repurchased706K

Avg price paid$417.87

Remaining$527M

MechanismNot specified

What the filing says

Medpace Holdings, Inc. (Nasdaq: MEDP) repurchased 705,616 shares for a total of $294.7 million during the second quarter of 2026, according to the company's earnings announcement filed on July 22, 2026. The execution mechanism is not specified in the filing, though open-market purchases under Rule 10b-18 are the standard approach for such repurchases.

As of June 30, 2026, the company had $527.0 million remaining under its authorized share repurchase program. The company generated $162.0 million in cash flow from operating activities during the second quarter and held $502.7 million in cash and cash equivalents, providing substantial liquidity for the repurchase activity and ongoing operations.

The buyback occurred during a period of strong financial performance, with second-quarter 2026 revenue of $707.3 million (up 17.2% year-over-year), GAAP net income of $121.4 million ($4.25 per diluted share), and EBITDA of $153.4 million (21.7% margin). The company's 2026 full-year guidance does not include the potential impact of any additional share repurchases after June 30, 2026.

During the second quarter of 2026, the Company repurchased 705,616 shares for a total of $294.7 million. As of June 30, 2026, the Company had $527.0 million remaining under its authorized share repurchase program. — Medpace Holdings, Inc. 8-K filing · View on SEC EDGAR →

What this means

Medpace executed a substantial share buyback in Q2 2026 totaling nearly $295 million, reducing diluted share count from 29.143 million at end of Q2 2025 to 28.554 million at end of Q2 2026 (based on weighted-average shares outstanding). With $527 million of authorization remaining and strong operating cash flow ($313.8 million for the first half of 2026), the company retains significant capacity for additional repurchases. The buyback represents a capital allocation decision reflecting management's view of intrinsic value relative to the market price, though the filing contains no commentary on valuation rationale.

Frequently asked questions

How much did Medpace spend on share repurchases in Q2 2026?: Medpace repurchased 705,616 shares for a total of $294.7 million during the second quarter of 2026, implying an average price of approximately $417.87 per share.
How much authorization remains for future repurchases?: As of June 30, 2026, the company had $527.0 million remaining under its authorized share repurchase program. This gives management substantial capacity to continue buybacks in subsequent periods.
Does this buyback activity reduce future earnings per share?: The company's 2026 full-year EPS guidance ($17.25–$17.95) is explicitly stated not to include the potential impact of any share repurchases after June 30, 2026. Fewer shares outstanding would generally increase per-share earnings, all else equal, but management has not incorporated post-H1 repurchases into its forward guidance.
What was the execution mechanism for these repurchases?: The filing does not specify the mechanism used (e.g., Rule 10b-18 open-market purchases, ASR, or 10b5-1 plan). Such details are often disclosed in later periodic filings rather than in quarterly earnings releases.
Did Medpace have sufficient cash to fund this buyback?: Yes. Medpace held $502.7 million in cash and cash equivalents at June 30, 2026, and generated $162.0 million in operating cash flow during Q2 2026 alone, easily covering the $294.7 million repurchase.
Why doesn't the company's 2026 guidance include the impact of future repurchases?: Management typically excludes potential future buybacks from guidance because the timing, price, and magnitude of repurchases are discretionary and uncertain. The guidance assumes 28.6 million diluted weighted-average shares outstanding for the full year 2026, implying no material buyback impact from July onward.

execution medpace cro-sector q2-2026 rule-10b-18

Source. This editorial summary is based on the SEC filing linked above. BuybackStocks aggregates and editorializes publicly available SEC EDGAR filings. Not investment advice. Past authorization announcements do not guarantee future repurchase activity or share price performance. See our full disclosures policy.